Inflammatory Diseases
CV6 is developing therapies for inflammatory diseases based on the same underlying biological approach used in oncology.
By targeting uracil-DNA metabolism, these programs aim to address key drivers of disease and support the development of potentially more durable treatment approaches.
CV6-1271
CV6-1271 is a lead preclinical candidate for inflammatory diseases, including rheumatoid arthritis.
Early studies demonstrate activity in disease models, supporting further development toward clinical evaluation.
CV6-1271: Current pHase
Preclinical